VIDEO

Introducing ioGlutamatergic Neurons HTT 50CAG/WT | A next-generation approach to study Huntington's disease

2022
Dr Tony Oosterveen, Senior Scientist | Dr Zoe Nilsson, Global Product Marketing Manager | Ben Newman, Scientist
bit.bio

 

Summary

Watch this video to learn about the exciting first product from bit.bio’s new ioDisease Model portfolio, ioGlutamatergic Neurons HTT50CAG/WT for Huntington’s disease research and drug discovery.


In this video, you will learn about the development of the human iPSC-derived glutamatergic neurons with a 50 CAG repeat expansion, the power of opti-ox powered disease models and the benefit of using genetically matched controls in the study of Huntington’s disease.


The bit.bio team offers insights
into the industry-leading consistency and scalability of ioGlutamatergic Neurons HTT50CAG/WT and the potential impact the disease model has on Huntington's disease research and drug discovery.


Find out more about the characterisation of our Huntington’s disease model in the brochure here.